Arcera Licenses Innogen’s GLP-1 Drug in Deal Valued Over $1 Billion
Abu Dhabi-based Arcera Life Sciences has entered an exclusive licensing agreement with China-based Innogen Pharmaceuticals to develop and commercialize the GLP-1 therapy efsubaglutide alfa. Arcera gains commercial rights across priority markets including the UAE, the Middle East, Africa, Eastern Europe, and Latin America. The transaction includes $15 million upfront, up to $38 million in near-term milestones, and future payments that could bring total deal value beyond $1 billion.

